Mevalonate kinase deficiency (MKD) is a rare inherited autoinflammatory disorder caused by mutations in the MVK gene, which encodes an enzyme involved in a critical biosynthetic pathway in cells.1PubMed Central. Mevalonate kinase deficiency: an updated clinical overview and revision of the SHARE recommendations The disease sits on a spectrum: at the milder end, it causes recurrent fever episodes historically called hyper-IgD syndrome (HIDS), and at the severe end, it causes a life-threatening condition known as mevalonic aciduria (MA).2PubMed Central. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome Because MKD is so rare and its symptoms overlap with other periodic fever syndromes, getting to a correct diagnosis can take years.
What Goes Wrong at the Cellular Level
Mevalonate kinase is the first dedicated enzyme in a pathway that produces cholesterol and a group of molecules called isoprenoids. Isoprenoids do a lot of behind-the-scenes work in cells, including attaching small chemical tags to proteins so those proteins can anchor to cell membranes and function properly. This tagging process is called prenylation.3PubMed Central. Mevalonate kinase deficiency: current perspectives When MVK mutations reduce the enzyme’s activity, prenylation falls short. Certain signaling proteins inside immune cells end up untagged and overactive, which triggers the Pyrin inflammasome, a molecular alarm system that drives the release of the inflammatory messenger IL-1β and causes immune cells to self-destruct in an inflammatory form of cell death.4PubMed Central. Pyrin inflammasome-driven erosive arthritis caused by unprenylated RHO GTPase signaling The result is waves of seemingly unprovoked inflammation that hit multiple organ systems at once.
How much enzyme activity a person retains determines where they fall on the severity spectrum. Someone with two mildly damaging MVK mutations may keep enough enzyme function to have periodic but manageable flares. Someone with two severely damaging mutations may have almost no enzyme activity, leading to the devastating neurological and systemic features of mevalonic aciduria.5PubMed Central. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome Intermediate phenotypes exist too, reinforcing that this is a continuum rather than two separate diseases.6Genes & Diseases. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review
The Clinical Spectrum
Milder Disease (Formerly HIDS)
At the milder end, patients experience recurrent fever episodes that typically begin in infancy, with a median age at first episode of about six months.7PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry In a large registry of 114 patients, attacks came roughly twelve times per year and involved gastrointestinal symptoms in nearly all patients, along with swollen lymph nodes, skin rashes, and joint or muscle pain. About 10 to 20 percent of patients reported ongoing fatigue or other constitutional symptoms even between attacks.8PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry Episodes usually last three to seven days, then resolve on their own until the next one. Historically, these patients were identified by elevated serum IgD levels, which gave the disease its earlier name of hyper-IgD syndrome. That label is now discouraged because high IgD is neither consistent in every patient nor unique to this disorder.9Genes & Diseases. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review
Severe Disease (Mevalonic Aciduria)
At the other extreme, mevalonic aciduria presents from birth or early infancy with a much broader and more devastating set of problems. The most severely affected children have profound developmental delay, distinctive facial features, cataracts, an enlarged liver and spleen, chronic anemia, and malabsorption. Some die in infancy.10PubMed. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria These children also experience the same inflammatory flares seen in milder MKD but on top of an already-compromised baseline, making management far more difficult. Neurological involvement, including cerebellar problems, was noted in a small number of patients in the Eurofever registry.11PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry
Getting a Diagnosis
MKD is easy to miss. A baby or toddler with recurring fevers, belly pain, and swollen glands often gets worked up for infections or more common periodic fever syndromes before anyone considers a metabolic-inflammatory disorder. The disease was originally thought to be concentrated in Northern Europe, but it has since been identified across many populations, partly because genetic testing is now more widely available.12European Journal of Human Genetics. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever
One useful screening tool is measuring mevalonic acid in urine. In a study of patients clinically suspected of having MKD, urinary mevalonic acid testing picked up the diagnosis with about 92 percent sensitivity and 90 percent specificity. The negative predictive value was 98 percent, meaning a normal urine result makes MKD very unlikely.13PubMed Central. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD) However, confirmation still requires genetic testing to identify the specific MVK mutations, since a handful of patients without mutations can have mildly elevated urinary mevalonic acid. In that same study, five out of 48 patients with no MVK mutations still had elevated levels, showing why the urine test alone is not the final word.14PubMed Central. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD)
Conditions That Look Similar
Several other recurrent fever syndromes share features with MKD and frequently come up earlier in the diagnostic process. Familial Mediterranean Fever (FMF) is the most common inherited periodic fever syndrome worldwide and causes episodes of fever with serositis and joint pain, which can overlap considerably with MKD flares. PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) is even more common in children and also features clockwork-like fever episodes with mouth sores and swollen neck glands. Case reports describe children initially managed for PFAPA or FMF who were eventually found to have MKD after standard treatments failed and genetic testing was pursued.15PubMed Central. Mevalonate kinase deficiency/Hyperimmunoglobulin D syndrome (MVK/HIDS) in a Differential Diagnosis of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Familial Mediterranean Fever (FMF): A Case Report A key clue can be the age of onset: MKD typically starts in the first year of life, and the triggers, particularly vaccinations, often stand out (more on that below). Still, awareness of MKD among general pediatricians remains low, and reaching a diagnosis in under a year is the exception rather than the rule.
Treatment With IL-1 Blockers
Because excessive IL-1β release is the central driver of MKD flares, the most effective treatments target that molecule. Canakinumab, a long-acting IL-1β antibody given by injection, is the best-studied option. In a large randomized controlled trial, 35 percent of MKD patients reached complete remission after 16 weeks at a standard dose, compared to just 6 percent on placebo. When the dose was increased, remission rates climbed to 57 percent, and even patients who did not reach complete remission had meaningfully fewer attacks.16PubMed Central. Management of Mevalonate Kinase Deficiency: A Pediatric Perspective – Section: Blocking Interleukin-1β
Anakinra, a shorter-acting IL-1 blocker given as a daily injection, offers a different approach. Some patients use it continuously, but a notable strategy is on-demand dosing: taking anakinra only at the start of a flare. In one study, on-demand anakinra shortened fever attacks by at least half in the majority of treated episodes among HIDS patients, though it did not change how often attacks occurred. Interestingly, anakinra also prevented vaccine-triggered flares without blocking the immune response to the vaccine itself.17PubMed. On-demand anakinra treatment is effective in mevalonate kinase deficiency However, the same study found anakinra had mixed results in patients with the more severe mevalonic aciduria form, with partial response in one patient and no response in another.18PubMed. On-demand anakinra treatment is effective in mevalonate kinase deficiency
When IL-1 Blockers Are Not Enough
A fraction of patients do not respond adequately to IL-1-targeted therapy, and in some parts of the world IL-1 blockers are simply not available. In those situations, clinicians have turned to other biologic agents. Tocilizumab, which blocks IL-6 signaling rather than IL-1, has shown promise in a handful of treatment-resistant cases. One report described a twelve-year-old girl whose severe MKD did not respond to either IL-1 or TNF-α blockade but who achieved complete clinical and laboratory remission after starting tocilizumab, sustained for 24 months.19PubMed Central. Tocilizumab for the Treatment of Mevalonate Kinase Deficiency A separate case series from China described two patients, one with MKD and one with another periodic fever syndrome, who had failed multiple prior therapies and achieved remission within one or two doses of tocilizumab.20PubMed Central. Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review These are small numbers, but they matter for patients who have run out of standard options.
Corticosteroids and NSAIDs are sometimes used as well, particularly to manage acute attacks. In the Eurofever registry, NSAIDs provided symptom relief for some patients, and steroids given during attacks appeared to help.21PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry Neither class of drug prevents flares from occurring, though, so they tend to play a supporting role alongside biologic therapy rather than serving as a long-term strategy on their own.
Stem Cell Transplant for Severe Cases
For children with the most severe mevalonic aciduria who do not respond to drug therapy, hematopoietic stem cell transplant (HSCT) is sometimes considered. The logic is straightforward: if the problem is that immune cells lack enough functional mevalonate kinase, replacing the bone marrow with donor cells that have normal enzyme activity should fix the inflammatory flares. Several early case reports supported this idea. One report documented a boy with severe MKD who received cord blood from an unrelated donor and remained in sustained remission during five years of follow-up, with normal developmental milestones and no late effects from the transplant.22PubMed. Long-term outcome of a successful cord blood stem cell transplant in mevalonate kinase deficiency A separate report described mevalonic aciduria cured by bone marrow transplantation.23PubMed. Mevalonic aciduria cured by bone marrow transplantation
However, the picture is not as clean as “transplant equals cure.” A more recent case report described a patient transplanted at 14 months who initially achieved complete engraftment and undetectable urinary mevalonate. Eighteen months later, she relapsed with fevers, rashes, and arthritis, and her urinary mevalonate rose again. She now requires ongoing treatment with steroids and canakinumab.24PubMed. Mevalonic aciduria: Does stem cell transplant fully cure disease? This was the first published relapse after transplant for mevalonic aciduria and challenges the assumption that HSCT is universally curative. It suggests transplant may reduce disease severity without fully eradicating it in every patient, which changes the risk-benefit conversation for families weighing a procedure that carries its own serious risks.
Long-Term Complications
Most MKD patients do well between attacks, but years of recurring inflammation can take a toll. The most feared long-term complication is AA amyloidosis, in which misfolded proteins from chronic inflammation gradually deposit in organs, especially the kidneys. In a comprehensive review of amyloidosis in MKD, 20 cases were identified, with kidney impairment as the initial sign in all of them. The authors estimated that about 6 percent of MKD patients may develop amyloidosis, though the true prevalence is hard to pin down because MKD itself is so rare.25PubMed. AA amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature Data from the Eurofever registry found AA amyloidosis in five out of 114 patients, which was roughly double what earlier, smaller cohorts had reported, and suggested the risk may have been underestimated.26PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry Certain genotype combinations appeared to carry higher risk: patients with the compound heterozygous combination p.V377I/p.I268T had amyloidosis significantly more often than other genotypes.27PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry
Other reported long-term issues include joint contractures, abdominal adhesions (from repeated peritoneal inflammation), kidney angiomyolipoma, and an increased susceptibility to severe pneumococcal infections.28PubMed Central. Natural history of mevalonate kinase deficiency: a literature review These complications reinforce why early effective treatment matters: the goal is not just to manage each flare but to reduce the cumulative inflammatory burden over a patient’s lifetime, which in turn lowers the risk of organ damage down the road.
Vaccinations and MKD
Vaccinations are one of the most reliable triggers of MKD flares, which puts families in a difficult position. In an Italian study of autoinflammatory disease patients, vaccines triggered disease activity in about 70 percent of MKD patients, a rate dramatically higher than the roughly 20 percent seen in patients with PFAPA or other periodic fever syndromes.29Annals of the Rheumatic Diseases. VACCINATION SAFETY AND COVERAGE IN AN ITALIAN COHORT OF AUTOINFLAMMATORY DISEASES When the researchers isolated vaccines as the sole cause of reactions (excluding other possible triggers), MKD patients still had the highest reaction rate at about 7 percent per shot, compared to around 1 percent or less for most other autoinflammatory conditions.30Annals of the Rheumatic Diseases. VACCINATION SAFETY AND COVERAGE IN AN ITALIAN COHORT OF AUTOINFLAMMATORY DISEASES
Importantly, no deaths, life-threatening events, or lasting disabilities were observed in the study. One MKD patient was hospitalized for a severe disease flare after a pneumococcal vaccine, but the overall rate of serious reactions across all autoinflammatory patients was low. This means the reactions are real and should be planned for, but they are not a reason to skip immunizations altogether. As noted earlier, on-demand anakinra given around the time of vaccination can prevent flares without blunting the antibody response.31PubMed. On-demand anakinra treatment is effective in mevalonate kinase deficiency Many MKD specialists now coordinate vaccination schedules with anakinra dosing to keep children protected against infections while minimizing post-vaccination episodes.
Genotype-Phenotype Patterns
Not all MVK mutations carry the same clinical weight, and the specific combination a patient inherits shapes the disease in ways that go beyond the simple mild-versus-severe divide. The p.V377I mutation is the most common variant seen in milder MKD and is found in a large proportion of patients in European registries. In the Eurofever cohort, patients who lacked a p.V377I mutation on either allele tended to have more severe musculoskeletal involvement.32PubMed. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry The condition follows autosomal recessive inheritance, meaning a child must inherit a faulty copy from each parent to develop the disease.33European Journal of Human Genetics. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever Carrier parents are typically asymptomatic.
Because the relationship between genotype and outcome is not perfectly predictable, clinicians generally rely on how a patient actually presents rather than making firm prognostic calls based on mutation data alone. That said, knowing the mutations can help families understand why their child’s disease behaves differently from another child’s, and it plays a role in genetic counseling for future pregnancies. The connection between the MVK gene and both severe mevalonic aciduria and the milder periodic fever form was not established until the late 1990s, and the recognition that these are a single disorder on a continuum is even more recent.34Genes & Diseases. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review That relatively short scientific history means the field’s understanding of genotype-phenotype correlations is still being refined as more patients are identified and followed long-term.